Our purpose in this paper was to examine the association of age, race, stage, grade, and calendar period with and generate estimates of disease-speci®c mortality after external beam radiation for prostate cancer. Using data from the Surveillance Epidemiology and End Results Program, we ®t proportional hazards models and used life table analyses to estimate survival distribution. High grade and stage, black race, and early calendar period were individually associated with disease-speci®c mortality. Disease-speci®c survival ranged from 43% for poorly differentiated regional cancer diagnosed in 1978±1982 to 88% for well differentiated localized cancer diagnosed in 1983±1987. Estimates of diseasespeci®c mortality varied by grade, stage and calendar period of diagnosis. These estimates may be considered in evaluating future treatments.
Introduction
Estimates of disease-speci®c mortality are useful in judging treatment ef®cacy and designing clinical trials. In the case of radiation treatment for prostate cancer, most reports of disease-speci®c mortality originate in academic and/or high volume treating centers. 1±4 The generalizability of these reports to the general American experience is theoretically limited because academic and/or highvolume centers can have outcomes that are better than those of nonacademic and/or low volume centers. 5, 6 Another potential limitation to generalizability originates in observations regarding the effects of calendar time on prostate cancer outcomes. In a rare reference to calendar time effects in prostate cancer radiation, a report of the Patterns of Care Study reports that`survival improved signi®cantly for the younger patients (by treatment year), 7 However, calendar time effects are a recognized phenomenon in many aspects of prostate cancer mortality. 8±10 We have recently shown, for example, that the relative risk of disease-speci®c mortality in patients who were treated with radiation or surgery dropped very signi®cantly from 1973±1990. 11 Potential partial explanations for varying outcomes by calendar time include variations in treated patient age, staging methods, and patterns of care, for example dissemination of external beam radiation in the early 1980s. 1, 3, 7, 12 Regardless of whether or not calendar time effects are due to cohort effects, stages of diagnosis and treatment, patient selection, and/or technical modi®cations of treatments, they can signi®cantly confound efforts to estimate clinical outcomes and cannot be ignored. In generalizing the results of reports that group patients across many years, for example from 1956±1992, 1 one must be cautious. Our purpose was to examine the association of age, stage, grade, and calendar period with disease-speci®c mortality and obtain relatively generalizable estimates of disease-speci®c mortality after external beam radiation for prostate cancer.
Methods

Patients
We used the 1973±1992 public-use tapes of the Surveillance, Epidemiology, and End Results (SEER) program and included all patients with prostate cancer except patients whose survival status was not known; we have previously described this database. 11 Data from the SEER program have been used to estimate trends in cancer incidence and mortality across the US. The program, set up to report population-based estimates of cancer incidence and mortality, includes cancer cases from geographic areas that are thought to capture approximately 14% of the US population. The participating states are Connecticut, Iowa, Utah, Hawaii, and New Mexico. The participating metropolitan areas are Detroit, MI; San Francisco-Oakland, CA; Seattle-Puget Sound, WA; and Atlanta, GA. After a diagnosis of cancer has been made by biopsy, variables are collected by retrospective hospital charts and/or medical record reviews. Active follow-up to verify vital status and cause of death is guided by local death, voter registration, driver license, and medical records. Cause of death is derived from local death certi®cates and is not recorded.
We examined only patients having only external beam radiation (SEER radiation code 1). Grade refers to the histological appearance of the tumor and is recorded as well-, moderately, poorly, or undifferentiated (anaplastic); undifferentiated tumors made up a trace proportion of all tumors and were excluded from analysis. Patients with distant (metastatic) and/or unknown stage were excluded from the analysis. Clinical stage was de®ned with the historic system: localized (T2) and regional (T3, Nx). Patients in whom stage or grade were unknown were excluded from analysis. To examine calendar time effects we de®ned three calendar periods: 1973±1977, 1987±1982, and 1983±1987. Patients diagnosed after 1987 were excluded from analysis because age-speci®c prostate cancer stage at diagnosis has been redistributed since 1988, probably because of the introduction of the prostate speci®c antigen (PSA) test. 13 
Statistical analysis
Cox proportional hazards regression model was used to investigate the impact of patient age and race, tumor grade and stage, and calendar period on disease-speci®c survival. We ®rst ®tted univariate models to evaluate the impact; those factors that were signi®cantly associated with survival in the univariate models were put into multivariate models to identify factor(s) that were independently associated with survival. Life-table methods were employed to estimate survivor distribution. Tenyear survival estimates and corresponding 95% con®-dence intervals were calculated. All P-values are twosided.
Results
The study cohort 
Factors associated with disease-speci®c survival
Results of proportional hazards analyses are presented in Table 2 . In univariate analysis, age was not signi®cantly associated with disease-speci®c survival. Multivariate proportional hazards analysis showed that grade, stage, race, and calendar period were independently associated with disease-speci®c mortality. Being black was associated with a 50% increase in disease-speci®c mortality after adjustments for grade, stage, and calendar period (P`0.0001). The analysis indicated that patients with poorly-differentiated tumors were more than three times more likely to die of prostate cancer than patients with well-differentiated tumors, even after controlling for stage, race, and calendar period (P`0.0001).
Estimated disease-speci®c survival
Estimated disease-speci®c survival by grade, stage, and time period of diagnosis is presented in Table 3 . Overall, disease-speci®c survival ranged from 43% for poorlydifferentiated regional cancer diagnosed in 1978±1982 to 88% for well-differentiated localized cancer diagnosed in 1983±1987. 
Discussion
The important strengths of the present study are that the study cohort is population-based and calendar time is adjusted for. These features allow relative con®dence in estimating disease-speci®c mortality after external beam radiation in the US. Within methodological constraints, the present estimates appear at least as good as those previously published from academic centers. Overall, in most stage and grade strata, disease-speci®c survival after external beam radiation in population-based patients is very good. The ®nding that age was not associated with diseasespeci®c mortality con®rms a previous suggestion that survival was good in older patients who have had radiation treatment. 7 We and others have shown that age is an important variable in the diagnosis and treatment of prostate cancer. 14, 15 One might reasonably conclude that the concern about age re¯ects primarily a concern about competing risk of overall death, not disease-speci®c death. Regardless of its origins, the selection of patients of varying ages for external beam radiation appears rational given that age was not associated with diseasespeci®c mortality.
A single-institution radiation case series has shown that black race is associated with higher tumor grade and lower disease-speci®c survival. 3 The present analysis extends these observations in demonstrating that the association of black race with lower disease-speci®c survival is prognostically informative individually of other variables, for example, grade, stage, time period of diagnosis. Because within clinical stage categories blacks have higher tumor volume than whites, 16 it is possible that the clinical stage is too gross a measure of disease to adjust the risk across race. It will be interesting to test in future studies if adjusting for serum PSA, which is higher in blacks, 16 will eliminate race as an independent risk factor.
Conclusions
One should be cautious in using the present observations in making inferences about relative treatment ef®cacy. Surgical series make use of pathological staging. By contrast, radiation and observation series make use of clinical staging. This basic fact, associated with the single treatment design of the present study, invalidate any direct comparisons of treatment ef®cacy. Also, one should recognize that SEER does not record the speci®c radiation fractionation regimes, total dose, ®eld size, and arrangement, which limits further speci®cation of survival. 
